Vaccination Uptake, Intent, and Confidence

At a glance

Monthly estimates of COVID-19, flu, and RSV vaccination uptake, intent to vaccinate, and vaccine confidence among adults are calculated using data from CDC’s National Immunization Survey. Data are available at the national and jurisdictional level

Overview

This monthly dashboard expands on the weekly COVID-19, flu, and RSV data available. It allows users to take a deeper dive into attitudes and behaviors associated with COVID-19, flu, and RSV vaccine uptake by a comprehensive set of demographic characteristics, behavioral and social drivers of vaccination, and barriers to vaccination.

Methods

Vaccination coverage estimates among adults 18 years and older are based on data from CDC's National Immunization Survey–Adult COVID Module. Estimates of vaccination coverage are based on respondent self-report. Estimates of vaccination coverage on this dashboard may vary from estimates on the weekly dashboard; weekly estimates are derived from compiling interview data from all prior weeks, while monthly estimates are derived only from interviews conducted that month.

Data Summary

COVID-19 and influenza vaccines

  • As of February 2025, 21.2% of adults 18+ in the U.S. have received a 2024–25 COVID-19 vaccine and 42.8% have received a 2024–25 flu vaccine.
    • Coverage is highest among adults ≥65 years (41.1% and 68.5%, respectively).
  • 8.3% and 4.8% of adults reported they definitely will get vaccinated with a 2024–25 COVID-19 vaccine and a 2024–25 influenza vaccine, respectively.
  • Concern about disease, confidence in vaccine safety, and confidence in the importance of the vaccine to prevent disease are factors associated with vaccine uptake.
    • Nationally, adults who expressed moderate to high concern about getting COVID-19 disease are more likely to have received a 2024–25 COVID-19 vaccine compared with adults who express little to no concern (35.5% vs. 13.0%). Adults who consider the vaccine safe and who consider the vaccine important to protect them are also more likely to have received the 2024–25 COVID-19 vaccine (38.2% vs. 4.8% and 33.9% vs. 1.8%, respectively).
    • Nationally, adults who expressed moderate to high concern about getting flu are more likely to have received a 2024–25 flu vaccine compared with adults who express little to no concern (57.2% vs. 36.2%). Adults who consider the vaccine safe and who consider the vaccine important to protect them are also more likely to have received the 2024–25 vaccine (60.7% vs. 19.5% and 58.8% vs. 8.9%, respectively).
  • The percent of adults reporting a healthcare provider had recommended vaccination since July 1, 2024, was 23.2% for COVID-19 and 42.2% for flu vaccine.
  • Few (6.1%) adults reported it was or would be somewhat or very difficult to get a COVID-19 vaccine.

RSV vaccine

  • As of February 2025, RSV vaccination coverage was 39.2% among adults aged ≥75 years and 35.9% among those aged 60–74 years at increased risk of severe RSV disease.
    • Among adults aged ≥75 years, 10.5% reported that they definitely will be vaccinated against RSV, and 12.7% among those aged 60–74 years at increased risk reported that they definitely will be vaccinated.
  • RSV vaccination coverage is lowest among Hispanic adults (17.4%) compared with other races and ethnicities among adults aged ≥75 years (e.g., 41.5% for non-Hispanic White adults).
  • Nationally, adults aged ≥75 years who expressed moderate to high concern about getting RSV are more likely to have received an RSV vaccine compared with adults who express little to no concern (50.2% vs. 32.9%). Adults who consider the vaccine safe and who consider the vaccine important to protect them are also more likely to have received the RSV vaccine (63.8% vs. 20.5% and 54.6% vs. 3.4%, respectively).
  • The percent of adults reporting a healthcare provider had recommended RSV vaccination was 37.8% among adults aged ≥75 years and 37.5% among those aged 60–74 years at increased risk of severe RSV disease.

Download Data